Crow's Feet
20
2
2
16
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 20 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
4 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (20)
Prospective, Non-interventional Study Assessing Perioral Rejuvenation Procedure
A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A
Efficacy and Safety of HMM1-022 in Temporary Correction of Crow's Feet
Non-invasive Rejuvenation of the Periorbital Area and Lower Eyelid
A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
Efficacy and Safety of DKB-119 in Patients in Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
ET-01 in Subjects With Lateral Canthal Lines
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Dose Finding Study In Subjects With Crow's Feet
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet